Urologic Imaging

What Imaging Is Best for Staging Nonseminoma After Orchiectomy? An ACR Workflow

·
What Imaging Is Best for Staging Nonseminoma After Orchiectomy? An ACR Workflow

A 28-year-old male presents for follow-up two weeks after a radical inguinal orchiectomy for a right testicular mass. The pathology report confirms a nonseminomatous germ cell tumor (NSGCT) with lymphovascular invasion. His post-operative tumor markers, including alpha-fetoprotein (AFP) and human chorionic gonadotropin (hCG), are still normalizing. As the treating urologist or oncologist, your immediate next step is to accurately stage the disease to determine the optimal management strategy, which could range from active surveillance to chemotherapy or surgery. This article details the American College of Radiology (ACR) Appropriateness Criteria for this exact clinical scenario: the initial staging of a pathologically confirmed nonseminoma. For evaluating the chest, the ACR finds that a standard Radiography chest is Usually appropriate.

Who Fits This Clinical Scenario?

This guidance applies specifically to patients who meet all the following criteria:

  • Diagnosis: A definitive histopathologic diagnosis of a nonseminomatous germ cell tumor (which includes embryonal carcinoma, yolk sac tumor, choriocarcinoma, and teratoma, or any combination) has been made.
  • Procedure: The diagnosis was established via radical inguinal orchiectomy.
  • Timing: This is the initial staging workup, performed after surgery but before any adjuvant therapy has been initiated.

This workflow is distinct from other related clinical situations. You should seek different guidance if your patient has:

  • Pure Seminoma: These tumors have a different pattern of spread and response to therapy, leading to a distinct staging and surveillance imaging pathway. This article does not apply.
  • Active Surveillance: A patient already staged with Stage I disease who is undergoing routine follow-up imaging has different pre-test probabilities and imaging goals.
  • Suspected Recurrence: A patient with rising tumor markers or new clinical symptoms after initial treatment requires an imaging workup focused on identifying recurrent or metastatic disease, which follows a separate ACR variant.

What Diagnoses Are You Working Up in This Scenario?

For a newly diagnosed nonseminoma, staging imaging is not about establishing a differential diagnosis of the primary tumor—that has been confirmed by pathology. Instead, the goal is to accurately map the extent of disease spread. The “differential” is the potential location and burden of metastases.

Retroperitoneal Lymphadenopathy This is the most common site of metastasis for testicular germ cell tumors. The lymphatic drainage of the testes follows a predictable path to the retroperitoneal lymph nodes—the para-aortic and paracaval nodes. Identifying and measuring the size of these nodes is the primary goal of abdominal imaging and is critical for distinguishing between Stage I (no spread) and Stage II (regional node involvement) disease.

Pulmonary Metastases The lungs are the second most common site of spread and the most frequent location for distant (Stage III) disease. Metastases often appear as well-defined, round nodules of varying sizes. While a chest radiograph can detect larger lesions, computed tomography (CT) is more sensitive for small-volume disease that could alter the patient’s prognosis and treatment plan.

Distant Visceral or Nodal Metastases Less commonly, nonseminomas can spread to other sites. This includes non-regional lymph nodes (such as mediastinal or supraclavicular nodes), the liver, brain, or bones. Identifying this level of spread is crucial as it defines Stage III disease and necessitates systemic chemotherapy. Brain metastases are more common with choriocarcinoma elements and very high hCG levels.

Why Is a Comprehensive Imaging Workup Recommended for Staging?

For the initial staging of nonseminoma, the ACR designates several imaging studies as Usually appropriate, reflecting the need to evaluate multiple anatomic regions. While a simple chest radiograph is a starting point for the lungs, a complete workup requires cross-sectional imaging of the abdomen and pelvis.

The standard of care for comprehensive staging involves:

  • CT abdomen and pelvis with IV contrast: This is the workhorse for evaluating the retroperitoneum. It is rated Usually appropriate. The use of intravenous contrast is essential to delineate blood vessels and accurately identify and measure lymph nodes, which may be subtly enlarged. This study provides the detailed anatomic map needed to plan for potential retroperitoneal lymph node dissection (RPLND) or to assess treatment response after chemotherapy. The radiation dose is in the ☢☢☢ 1-10 mSv range.
  • CT chest with IV contrast: Also rated Usually appropriate, this study is significantly more sensitive than a chest radiograph for detecting small pulmonary nodules. In many centers, a CT of the chest, abdomen, and pelvis is performed as a single, comprehensive staging examination.
  • Radiography chest: As a standalone study for the chest, this is rated Usually appropriate. It is a fast, low-cost, and very low-dose (☢ <0.1 mSv) method to screen for large-volume pulmonary metastases. However, its lower sensitivity for small nodules means many clinicians will proceed directly to a chest CT, often in conjunction with the abdominal/pelvic CT.
  • MRI abdomen and pelvis without and with IV contrast: This is another Usually appropriate option and serves as an excellent radiation-free alternative to CT for assessing the retroperitoneum. It is particularly valuable for younger patients to minimize cumulative radiation exposure or for those with a severe allergy to iodinated contrast. It has comparable accuracy to CT for detecting nodal disease.

Lower-Rated Alternatives

  • US abdomen and retroperitoneum: This is rated Usually not appropriate for staging. While ultrasound is excellent for evaluating the scrotum, it is unreliable for visualizing the deep retroperitoneal lymph nodes due to interference from overlying bowel gas and its operator-dependent nature.
  • FDG-PET/CT whole body: This is also Usually not appropriate for the initial staging of nonseminoma. While PET/CT is valuable for assessing residual masses after chemotherapy in seminoma, its role in initial nonseminoma staging is limited. CT provides the necessary anatomic detail for nodal size criteria, and PET/CT can have false positives and does not typically add enough information to justify the higher radiation dose (☢☢☢☢ 10-30 mSv) and cost at this stage.

What’s Next After Staging Scans? Downstream Workflow

The results of your staging imaging, combined with post-orchiectomy tumor marker levels, will directly guide the next steps in management according to established risk stratification.

  • If Imaging is Negative (Stage I): If the chest, abdomen, and pelvis CT scans show no evidence of metastatic disease and tumor markers have normalized, the patient has clinical Stage I nonseminoma. The primary management options include active surveillance, primary RPLND, or one to two cycles of adjuvant chemotherapy. The choice depends on risk factors identified in the orchiectomy specimen, such as the presence of lymphovascular invasion.
  • If Retroperitoneal Nodes are Positive (Stage II): If imaging reveals enlarged retroperitoneal lymph nodes, the patient has Stage II disease. Management depends on the bulk of disease and marker levels. Options include primary chemotherapy (typically three or four cycles of BEP: bleomycin, etoposide, and cisplatin) or, for low-volume disease, primary RPLND.
  • If Distant Metastases are Positive (Stage III): If imaging shows metastases in the lungs, liver, or other distant sites, the patient has Stage III disease. The standard of care is primary chemotherapy, with the specific regimen and number of cycles determined by the International Germ Cell Cancer Collaborative Group (IGCCCG) risk classification.

Pitfalls to Avoid (and When to Get Help)

Accurate staging is paramount in nonseminoma, and several common errors can lead to improper management.

  • Incomplete Staging: Ordering only a chest X-ray without cross-sectional imaging of the abdomen and pelvis is a critical error. The retroperitoneum is the most common site of spread and must be evaluated.
  • Omitting IV Contrast: A non-contrast CT of the abdomen and pelvis (CT abdomen and pelvis without IV contrast is only rated May be appropriate) significantly compromises the ability to detect and measure retroperitoneal lymph nodes. Always specify “with IV contrast” unless there is a clear contraindication.
  • Ignoring Tumor Markers: Imaging findings must always be correlated with post-orchiectomy tumor markers (AFP, hCG, LDH). Persistently elevated markers after orchiectomy, even with negative imaging, indicate the presence of residual microscopic disease (Stage IS) and necessitate treatment, typically with chemotherapy.
  • Misclassifying Histology: This workflow is exclusively for nonseminomas. Applying it to a pure seminoma is incorrect. If the pathology report shows a mixed germ cell tumor with both seminoma and nonseminoma components, it should be managed according to nonseminoma guidelines.

If you encounter a complex case with discordant imaging and marker results, or if there is evidence of brain metastases, consultation with a multidisciplinary tumor board at a high-volume cancer center is strongly recommended.

Related ACR Topics and Tools

This article covers one specific scenario in depth. For a broader view of the topic or to explore adjacent clinical questions, the following resources are available.

Frequently Asked Questions

Is a chest X-ray enough for staging, or is a chest CT always needed for nonseminoma?

While a chest radiograph is rated ‘Usually appropriate’ by the ACR and can detect large-volume lung metastases, a CT of the chest is far more sensitive for small nodules. Most oncology guidelines and clinical practices favor a chest CT as part of the initial staging workup for nonseminoma to ensure no small-volume disease is missed, as this can impact risk stratification and treatment planning. It is often performed at the same time as the CT of the abdomen and pelvis.

My patient has a severe IV contrast allergy. Is MRI a good substitute for CT of the abdomen and pelvis?

Yes. For patients with a contraindication to iodinated contrast, ‘MRI abdomen and pelvis without and with IV contrast’ (using a gadolinium-based agent) is also rated ‘Usually appropriate’ and is an excellent alternative. It has comparable diagnostic accuracy to CT for detecting and measuring retroperitoneal lymphadenopathy.

Why isn’t PET/CT recommended for the initial staging of nonseminoma?

FDG-PET/CT is rated ‘Usually not appropriate’ for this specific scenario. The primary reason is that CT provides the crucial anatomical detail—specifically, lymph node size—which is the basis for clinical staging. PET/CT adds significant radiation dose and cost without providing sufficient additional information to change management at this initial stage. Its main role is in assessing residual masses after chemotherapy, particularly in seminoma.

What if the pathology report says it’s a mixed germ cell tumor with both seminoma and nonseminoma parts?

Any testicular germ cell tumor that contains nonseminomatous elements is treated as a nonseminoma, regardless of the percentage of each component. Therefore, you should follow the imaging and management guidelines for nonseminoma detailed in this article.

Should every patient with nonseminoma get a brain MRI at initial staging?

No, routine brain imaging is not recommended for all patients. ‘MRI head without and with IV contrast’ is rated ‘May be appropriate’. It should be considered in patients with specific risk factors, such as the presence of choriocarcinoma in the primary tumor, very high hCG levels (>50,000 IU/L), or clinical symptoms suggestive of central nervous system involvement.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 29, 2026